# Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)

> **NCT02806362** · PHASE3 · WITHDRAWN · sponsor: **AbbVie**

## Conditions studied

- Chronic Hepatitis C Virus

## Interventions

- **DRUG:** Ombitasvir/paritaprevir/ritonavir

## Key facts

- **NCT ID:** NCT02806362
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09
- **Primary completion:** 2018-06
- **Final completion:** 2018-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study halted prematurely, prior to enrollment of first participant
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02806362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02806362, "Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02806362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*